The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. It can protect against HIV ...

The incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir compared with daily oral emtricitabine-tenofovir disoproxil fumarate.

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Gilead Sciences has announced the outcomes from the Phase III PURPOSE 2 trial evaluating lenacapavir for HIV prevention.

One study revealed that injection of the medication lenacapavir every six months could greatly reduce the risk for HIV infection among at-risk individuals. Human immunodeficiency virus (HIV ...

Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons,” published in the November 2024 issue of Infectious ...